Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Squamous Cell Carcinoma of Head and Neck 3Lymphoma 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Brenner Tumor 1

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × VTX-2337 × Clear all
NCT00688415 2019-09-25

Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer

Celgene

Phase 1 Completed
33 enrolled
Lymphoid

Lymphoma

NCT01289210 2019-09-25

VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Celgene

Phase 1/2 Terminated
2 enrolled 4 charts
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡